Skip to main content

T2DM

2
Pipeline Programs
5
Companies
7
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
3100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

HighTide Therapeutics
HighTide TherapeuticsChina - Shenzhen
1 program
1
HTD1801Phase 21 trial
Active Trials
NCT07496177Not Yet Recruiting75Est. Jun 2027
Pegbio
PegbioChina - Hangzhou
1 program
1
Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059))Phase 1Peptide1 trial
Active Trials
NCT07347080Recruiting9Est. Aug 2026
Celltrion
CelltrionKorea - Incheon
2 programs
CT-L03 Group 1PHASE_31 trial
MetforminPHASE_31 trial
Active Trials
NCT06571591Active Not Recruiting582Est. May 2026
NCT07093476Recruiting171Est. Apr 2027
Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
2 programs
EcnoglutidePHASE_3Peptide1 trial
Ecnoglutide high dosagePHASE_3Peptide1 trial
Active Trials
NCT05680155Completed211Est. Oct 2024
NCT05680129Completed623Est. Oct 2024
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
ChiglitazarPHASE_11 trial
Active Trials
NCT05681273Completed48Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
CelltrionMetformin
CelltrionCT-L03 Group 1
Sciwind BiosciencesEcnoglutide high dosage
Sciwind BiosciencesEcnoglutide
HighTide TherapeuticsHTD1801
PegbioExenatide Circular RNA-Lipid Nanoparticle Injection( CR059))
Chipscreen BiosciencesChiglitazar

Clinical Trials (7)

Total enrollment: 1,719 patients across 7 trials

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Start: Jul 2025Est. completion: Apr 2027171 patients
Phase 3Recruiting
NCT06571591CelltrionCT-L03 Group 1

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Start: Aug 2024Est. completion: May 2026582 patients
Phase 3Active Not Recruiting
NCT05680129Sciwind BiosciencesEcnoglutide high dosage

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Start: Jan 2023Est. completion: Oct 2024623 patients
Phase 3Completed

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Start: Dec 2022Est. completion: Oct 2024211 patients
Phase 3Completed

A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.

Start: May 2026Est. completion: Jun 202775 patients
Phase 2Not Yet Recruiting
NCT07347080PegbioExenatide Circular RNA-Lipid Nanoparticle Injection( CR059))

A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

Start: Jan 2026Est. completion: Aug 20269 patients
Phase 1Recruiting

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Start: Feb 2023Est. completion: Mar 202348 patients
Phase 1Completed

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,719 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.